Waldenstrom macroglobulinemia
Also known as Waldenstrom's macroglobulinemia, Waldenström Macroglobulinemia, Waldenström macroglobulinemia, lymphoplasmacytic lymphoma with IgM gammopathy+4 more
Waldenstrom's macroglobulinemia, Waldenström Macroglobulinemia, Waldenström macroglobulinemia, lymphoplasmacytic lymphoma with IgM gammopathy, Waldenstroem's macroglobulinemia, Waldenstrom's macroglobulinaemia, Waldenstrom's syndrome, macroglobulinemia of Waldenstrom.
Recent clinical, regulatory, research and industry developments relating to this disease.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 3 clinical trials expected to report results, the earliest in Q3 2026.
- Q3 2026An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination With Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia
- Q1 2028Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia
- Q1 2029A Phase II Study Evaluating Venetoclax and Pirtobrutinib in Previously Treated Waldenström Macroglobulinemia
Clinical MilestonesViewHide
- 2026-05-28A Phase II Study Evaluating Venetoclax and Pirtobrutinib in Previously Treated Waldenström MacroglobulinemiaResults expected Q1 2029
- 2026-05-05Efficacy of Venetoclax in Combination With Rituximab in Waldenström's MacroglobulinemiaResults expected Q1 2028
- 2026-01-02An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination With Zanubrutinib (BGB-3111) in Patients With Waldenström MacroglobulinemiaResults expected Q3 2026
- 2026-05-01A Phase II Study Evaluating Loncastuximab Tesirine in Patients With Previously Treated Waldenström MacroglobulinemiaPrimary completion
- 2025-12-31A Multi-Center, Open-Label, Single-Arm Phase II Trial of Bendamustine, Rituximab and the Second Generation BTK Inhibitor Acalabrutinib in Previously Untreated Waldenstrom's MacroglobulinemiaPrimary completion
- 2026-05-28ClinicalA Phase II Study Evaluating Venetoclax and Pirtobrutinib in Previously Treated Waldenström MacroglobulinemiaResults expected Q1 2029
- 2026-05-05ClinicalEfficacy of Venetoclax in Combination With Rituximab in Waldenström's MacroglobulinemiaResults expected Q1 2028
- 2026-05-01ClinicalA Phase II Study Evaluating Loncastuximab Tesirine in Patients With Previously Treated Waldenström MacroglobulinemiaPrimary completion
- 2026-02-03ClinicalPhase II Study of Ibrutinib in Combination With Ixazomib in Patients With Waldenström MacroglobulinemiaTerminated
- 2026-01-02ClinicalAn Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination With Zanubrutinib (BGB-3111) in Patients With Waldenström MacroglobulinemiaResults expected Q3 2026
- 2025-12-31ClinicalA Multi-Center, Open-Label, Single-Arm Phase II Trial of Bendamustine, Rituximab and the Second Generation BTK Inhibitor Acalabrutinib in Previously Untreated Waldenstrom's MacroglobulinemiaPrimary completion
Clinical trials
The current development programme across all trial phases.
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
A lymphoproliferative disorder characterized by pleomorphic B-LYMPHOCYTES including PLASMA CELLS, with increased levels of monoclonal serum IMMUNOGLOBULIN M. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include ANEMIA; HEMORRHAGES; and hyperviscosity.
Waldenstrom's macroglobulinemia, Waldenström Macroglobulinemia, Waldenström macroglobulinemia, lymphoplasmacytic lymphoma with IgM gammopathy, Waldenstroem's macroglobulinemia, Waldenstrom's macroglobulinaemia, Waldenstrom's syndrome, macroglobulinemia of Waldenstrom
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Related entities are derived from literature co-mention (studied together) — associative, not causal.